FDA puts Immunomedics cancer drug trial on hold
(Reuters) - Immunomedics Inc said on Thursday that the U.S. health regulator put a partial hold on the company's pancreatic cancer drug trial after a patient was given an incorrect dose.
Immunomedics, which develops antibody-based products for treatment of cancer, autoimmune and other diseases, said the patient was inadvertently given a higher dose of the drug, clivatuzumab tetraxetan.
The company clarified that the U.S. Food and Drug Administration's decision was not based on safety issues of the drug.
Immunomedics added that the patient is still enrolled in the trial phase Ib/II, but has not received any further dose.
Shares of Morris Plains, New Jersey-based Immunomedics closed down 6 percent at $3.50 on Thursday on Nasdaq.
(Reporting by Kavyanjali Kaushik in Bangalore; Editing by Roshni Menon)
- Malaysia says no evidence missing plane flew hours after losing contact |
- Missing jet may have strayed to west, Malaysia military says |
- UPDATE 1-U.S. investigators suspect missing Malaysian plane flew for hours -WSJ
- Malaysia failing credibility test as flight confusion deepens
- NYC buildings explosion kills 6, others missing